The American Gastroenterological Association (AGAI) Technical Review on the Management of Barrett's Esophagus provides a comprehensive evaluation of diagnostic and management strategies for patients at risk or diagnosed with Barrett's esophagus. The review addresses key questions related to the definition of Barrett's esophagus, the identification of the gastroesophageal junction (GEJ), the type of epithelium required for diagnosis, the extent of metaplasia, cancer risk, life expectancy, quality of life, risk factors, and screening recommendations. Barrett's esophagus is defined as the condition in which metaplastic columnar epithelium replaces the normal stratified squamous epithelium of the distal esophagus. The GEJ is a critical landmark for diagnosis, but there is no universally accepted method for identifying it. The review discusses the use of the proximal extent of gastric folds and the distal extent of palisade vessels as potential landmarks, though both have limitations. The review also addresses the types of epithelium involved in Barrett's esophagus, noting that intestinal-type epithelium is more clearly associated with cancer risk than gastric-type or cardia-type epithelium. The extent of metaplasia is important for determining cancer risk, with longer segments having a higher risk. The review emphasizes the need for accurate identification of the GEJ and the importance of measuring the extent of metaplasia for clinical decision-making. The risk of esophageal cancer in patients with Barrett's esophagus is estimated at approximately 0.5% per year, with higher risks in those with dysplasia. The review also discusses the impact of Barrett's esophagus on quality of life, noting that patients often experience significant psychological stress and increased healthcare costs. Risk factors for Barrett's esophagus include advanced age, male sex, white ethnicity, GERD, hiatal hernia, elevated BMI, and intra-abdominal fat distribution. Screening for Barrett's esophagus is recommended for individuals with chronic GERD symptoms, though the benefits of endoscopic screening are debated due to the low absolute risk of cancer and potential for overdiagnosis. The natural history of dysplasia in Barrett's esophagus is discussed, with high-grade dysplasia having a higher risk of progression to cancer. The review highlights the challenges in diagnosing low-grade dysplasia and the importance of accurate biopsy sampling. The review concludes that while there is no direct evidence supporting the utility of endoscopic screening for Barrett's esophagus, individualized decisions should be made based on patient-specific factors. The review also emphasizes the need for further research to improve the accuracy of diagnosis and management strategies for Barrett's esophagus.The American Gastroenterological Association (AGAI) Technical Review on the Management of Barrett's Esophagus provides a comprehensive evaluation of diagnostic and management strategies for patients at risk or diagnosed with Barrett's esophagus. The review addresses key questions related to the definition of Barrett's esophagus, the identification of the gastroesophageal junction (GEJ), the type of epithelium required for diagnosis, the extent of metaplasia, cancer risk, life expectancy, quality of life, risk factors, and screening recommendations. Barrett's esophagus is defined as the condition in which metaplastic columnar epithelium replaces the normal stratified squamous epithelium of the distal esophagus. The GEJ is a critical landmark for diagnosis, but there is no universally accepted method for identifying it. The review discusses the use of the proximal extent of gastric folds and the distal extent of palisade vessels as potential landmarks, though both have limitations. The review also addresses the types of epithelium involved in Barrett's esophagus, noting that intestinal-type epithelium is more clearly associated with cancer risk than gastric-type or cardia-type epithelium. The extent of metaplasia is important for determining cancer risk, with longer segments having a higher risk. The review emphasizes the need for accurate identification of the GEJ and the importance of measuring the extent of metaplasia for clinical decision-making. The risk of esophageal cancer in patients with Barrett's esophagus is estimated at approximately 0.5% per year, with higher risks in those with dysplasia. The review also discusses the impact of Barrett's esophagus on quality of life, noting that patients often experience significant psychological stress and increased healthcare costs. Risk factors for Barrett's esophagus include advanced age, male sex, white ethnicity, GERD, hiatal hernia, elevated BMI, and intra-abdominal fat distribution. Screening for Barrett's esophagus is recommended for individuals with chronic GERD symptoms, though the benefits of endoscopic screening are debated due to the low absolute risk of cancer and potential for overdiagnosis. The natural history of dysplasia in Barrett's esophagus is discussed, with high-grade dysplasia having a higher risk of progression to cancer. The review highlights the challenges in diagnosing low-grade dysplasia and the importance of accurate biopsy sampling. The review concludes that while there is no direct evidence supporting the utility of endoscopic screening for Barrett's esophagus, individualized decisions should be made based on patient-specific factors. The review also emphasizes the need for further research to improve the accuracy of diagnosis and management strategies for Barrett's esophagus.